In the Media
Are you looking for the latest media coverage of the BioMed X Institute, its research projects and people behind the innovation model? Here you will find the latest clippings – hot off the press!
Visit: BioMed X begins research project for oral therapeutics delivery
BioMed X begins research project for oral therapeutics delivery
manufacturing Chemist
The collaboration with Janssen Research and Development was facilitated by Johnson & Johnson Innovation.
Visit: El Instituto BioMed X inicia un nuevo proyecto de investigación sobre administración de fármacos en colaboración con Janssen
El Instituto BioMed X inicia un nuevo proyecto de investigación sobre administración de fármacos en colaboración con Janssen
FarmaIndustrial
El instituto de investigación independiente alemán BioMed X anuncia su nuevo proyecto de investigación con Janssen Research & Development, una de las compañías farmacéuticas Janssen de Johnson & Johnson, que se esforzará por descubrir nuevos mecanismos de transporte en el tracto intestinal humano que podrían utilizarse para la administración oral de diversas modalidades terapéuticas.
Visit: BioMed X, Janssen Enter Oral Drug Delivery Alliance
BioMed X, Janssen Enter Oral Drug Delivery Alliance
ContractPharma
Aims to discover novel transport mechanisms which could be utilized for oral delivery of therapeutic modalities.
Visit: BioMed X Launches Drug Delivery Research Project with Janssen
BioMed X Launches Drug Delivery Research Project with Janssen
BioPharm International
The project is aimed at discovering novel transport mechanisms in the human intestinal tract that could be used for oral delivery of diverse therapeutic modalities.
Visit: Crowdsourcing and open innovation in drug discovery: recent contributions and future directions
Crowdsourcing and open innovation in drug discovery: recent contributions and future directions
Drug Discovery Today
The past decade has seen significant growth in the use of ‘crowdsourcing’ and open innovation approaches to engage ‘citizen scientists’ to perform novel scientific research. Here, we quantify and summarize the current state of adoption of open innovation by major pharmaceutical companies.